illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. GC Biopharma
Company logo

GC Biopharma | Sustainability Performance

https://www.gcbiopharma.com/eng/index.do

Develops, manufactures, and markets biopharmaceutical and vaccine products.

1967

South Korea

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6400
Overall
#60
in South Korea
#135
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

234 out of 311

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Seegene

South Korea, Health Care, Biotechnology

Company logo
Suheung

South Korea, Health Care, Pharmaceuticals

Company logo
Shinpoong Pharm

South Korea, Health Care, Pharmaceuticals

Market cap

1.5T $, 2026▼3.6% YoY

Revenue

1.7T $, 2024▼3.2% YoY

R&D intensity

9.89% 2024

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • GC Biopharma Corporation (formerly Green Cross), Korean blood products major, has faced multiple US FDA Form 483 observations at multiple production facilities including the contested historic 2023 enforcement actions on quality systems, plus periodic Korean FSC enforcement scrutiny on inadequate disclosure of US blood products customer concentration affecting institutional shareholders.
Powered by illuminem

Market cap

1.5T $, 2026▼3.6% YoY

Revenue

1.7T $, FY2024▼3.2% YoY

EBITDA

46.5B $, FY2024▼9.1% YoY

Operating margin

2% Industry: -33▲10.8% YoY

P/E ratio

-78.0 Industry: 26▼31% YoY

Revenue & EBITDA

$1.7TFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends

Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-95.9B 2024▲37.1% YoY

Capex

42.4B 2024▲197.2% YoY

Debt/equity ratio

0.7 Industry: 0▼NaN% YoY

R&D intensity

9.9%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

-1.0%FY2026
Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals

Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

1.7K

▲ 3.6%

2022

1.6K

▼ 2.1%

2023

1.7K

▼ 1.8%

2024

2.4K

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Available

Human rights policy

Available

Recycling policy

Available

Workplace health & safety policy

Available

31%
Independent Directors

4 out of 13 incl. management

Powered by illuminem

Overall score

84

Environment

99

Social

99

Governance

54

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
Not committed to key sustainability initiatives

Sustainability employees

    Available in
    Scale package

    Access
  • Email
  • Email